Cargando…

Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies

Chimeric antigen receptor T cell (CART) therapy is currently one of the most promising treatment approaches in cancer immunotherapy. However, the immunosuppressive nature of the tumor microenvironment, in particular increased reactive oxygen species (ROS) levels, provides considerable limitations. I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoo, Hyeon Joo, Liu, Yibin, Wang, Lei, Schubert, Maria-Luisa, Hoffmann, Jean-Marc, Wang, Sanmei, Neuber, Brigitte, Hückelhoven-Krauss, Angela, Gern, Ulrike, Schmitt, Anita, Müller-Tidow, Carsten, Dreger, Peter, Mokhir, Andriy, Schmitt, Michael, Sellner, Leopold
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566309/ https://www.ncbi.nlm.nih.gov/pubmed/31109083 http://dx.doi.org/10.3390/ijms20102469

Ejemplares similares

Optimized Assessment of qPCR-Based Vector Copy Numbers as a Safety Parameter for GMP-Grade CAR T Cells and Monitoring of Frequency in Patients
por: Kunz, Alexander, et al.
Publicado: (2020)

Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients
por: Hoffmann, Jean-Marc, et al.
Publicado: (2018)

Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells
por: Yang, Mingya, et al.
Publicado: (2020)

Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19-positive malignancies
por: Wang, Sanmei, et al.
Publicado: (2021)

Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy
por: Yang, Mingya, et al.
Publicado: (2021)

Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol
por: Schubert, Maria-Luisa, et al.
Publicado: (2019)

HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma
por: Gong, Wenjie, et al.
Publicado: (2022)

Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
por: Hofmann, Susanne, et al.
Publicado: (2019)

Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells
por: Gong, Wenjie, et al.
Publicado: (2021)

Definition and Characterization of SOX11-Derived T Cell Epitopes towards Immunotherapy of Glioma
por: Liu, Yibin, et al.
Publicado: (2023)

Assessment of CAR T Cell Frequencies in Axicabtagene Ciloleucel and Tisagenlecleucel Patients Using Duplex Quantitative PCR
por: Schubert, Maria-Luisa, et al.
Publicado: (2020)

Shaping of CD56(bri) Natural Killer Cells in Patients With Steroid-Refractory/Resistant Acute Graft-vs.-Host Disease via Extracorporeal Photopheresis
por: Ni, Ming, et al.
Publicado: (2019)

Sensitivity and Specificity of CD19.CAR-T Cell Detection by Flow Cytometry and PCR
por: Schanda, Nicola, et al.
Publicado: (2021)

Comparison of single copy gene-based duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19-directed CAR T cells in treated patients
por: Schubert, Maria-Luisa, et al.
Publicado: (2022)

Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects
por: Wang, Lei, et al.
Publicado: (2018)

Impact of serum-free media on the expansion and functionality of CD19.CAR T-cells
por: Eberhardt, Franziska, et al.
Publicado: (2023)

Infection Complications after Lymphodepletion and Dosing of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or B Cell Non-Hodgkin Lymphoma
por: Korell, Felix, et al.
Publicado: (2021)

Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy
por: Stock, Sophia, et al.
Publicado: (2019)

Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells
por: Reichman, Avinoam, et al.
Publicado: (2022)

Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV
por: Bunse, Lukas, et al.
Publicado: (2022)

An Endoplasmic Reticulum Specific Pro‐amplifier of Reactive Oxygen Species in Cancer Cells
por: Xu, Hong‐Gui, et al.
Publicado: (2021)

Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL
por: Korell, Felix, et al.
Publicado: (2020)

First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma
por: Korell, Felix, et al.
Publicado: (2023)

Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial
por: Schubert, Maria-Luisa, et al.
Publicado: (2023)

Cell-based immunotherapy approaches for multiple myeloma
por: Kriegsmann, Katharina, et al.
Publicado: (2018)

Peptide Vaccination against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients
por: Sommerer, Claudia, et al.
Publicado: (2021)

Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data
por: Derigs, Patrick, et al.
Publicado: (2020)

The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy
por: Schubert, Maria-Luisa, et al.
Publicado: (2021)

Intracellular Amplifiers of Reactive Oxygen Species Affecting Mitochondria as Radiosensitizers
por: Xu, Hong-Gui, et al.
Publicado: (2021)

EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy—A Cohort Study
por: Korell, Felix, et al.
Publicado: (2022)

Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trial
por: Morath, Christian, et al.
Publicado: (2022)

Pre-transplant EASIX and sepsis after allogeneic stem cell transplantation
por: Korell, Felix, et al.
Publicado: (2022)

Response to Vaccination with Sars-CoV2 Vaccines in Patients Post Allogeneic Hematopoietic Cell Transplantation
por: Pabst, Caroline, et al.
Publicado: (2022)

Cure of intravascular NK/T-cell lymphoma of the central nervous system by allogeneic hematopoietic cell transplantation
por: Meissner, Julia, et al.
Publicado: (2022)

Definition and characterization of novel HLA-*A02-restricted CD8(+) T cell epitopes derived from JCV polyomavirus with clinical relevance
por: Mani, Jiju, et al.
Publicado: (2016)

Impact of Clinical Parameters and Induction Regimens on Peripheral Blood Stem-Cell Mobilization and Collection in Multiple Myeloma Patients
por: Sauer, Sandra, et al.
Publicado: (2023)

Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
por: Sauer, Sandra, et al.
Publicado: (2023)

Peptide vaccination in the presence of adjuvants in patients after hematopoietic stem cell transplantation with CD4+ T cell reconstitution elicits consistent CD8+ T cell responses
por: Schmitt, Michael, et al.
Publicado: (2017)

Humoral Responses and Chronic GVHD Exacerbation after COVID-19 Vaccination Post Allogeneic Stem Cell Transplantation
por: Pabst, Caroline, et al.
Publicado: (2022)

Triggering RNA Interference by Photoreduction under Red Light Irradiation
por: Rühle, Jennifer, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_udff9jnv98oucangmshdi001nc